Jefferies Starts ProNAi Therapeutics (DNAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Wedbush Starts ProNAi Therapeutics (DNAI) at Outperform
August 10, 2015 7:34 AM EDTWedbush initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Outperform rating and a price target of $36.00.
Analyst David Nierengarten commented, "DNAI is a clinical-stage biotech company developing a novel therapeutic platform based on DNA interference (DNAi). ProNAi's lead candidate, PNT2258, is a... More
BofA/Merrill Lynch Starts ProNAi Therapeutics (DNAI) at Buy
August 10, 2015 7:26 AM EDTBofA/Merrill Lynch initiated coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Buy rating and a price target of $35.00.
For an analyst ratings summary and ratings history on ProNAi Therapeutics click here. For more ratings news on ProNAi Therapeutics click here.
Shares of ProNAi Therapeutics closed at $28.56 yesterday.
... More